Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My bad.
From the S-1:
"The first units off the tooling have been submitted for testing to ensure they meet ASTM standards (American Society of Testing and Materials); the Company received a passing grade from ASTM in May 2010 (when ASTM tests products to ensure they meet ASTM’s standards, ASTM provides either a pass or fail grade). Concurrently, a required premarket notification, known as a 510(k), was filed with the FDA. A predicate device manufactured by this Chinese company already has an FDA approval, so no further clinical trials are required. The Company has engaged an FDA consultant to help guide it through the 510(k) filing process."
However, it appears to be just a formality.
CE,
I'm not following. It was my understanding that the new thermometer already does have FDA approval and this was obtained some time ago?
Okay, thanks.
makeamint2,
You mention there has to be a po. Wondering if you could expand on that point? TIA
ty,
Any word on whether this was a consignment sale?
Nice to see the shipping of goods may be starting in earnest!
Thanks, I think it's still helpful.
By the way makeamint2, I would agree that it's quite possible that some of the new financing obtained could have required the restrictions to remain in place. I still look at this as a positive because these people are doing what is necessary to obtain financing necessary to get the company to the next level. They could have just had the restrictions lifted, dumped the shares and let the company flounder. They continue to make the required filings and disclosures, something many pinks fail to do. It does not appear to me that they are just "selling shares" to benefit insiders as some have claimed.
Why would more rounds of comments mean dimmer prospects? Just trying to understand. TIA
Fair enough makeamint2. In regards to the SEC comments, are you saying we may be close to finalizing the process?
All good points Curt. I think most important is that sales should be picking up, especially in the 4th quarter.
Please provide evidence to support your claim that they were required to leave the restrictions in place. I see nothing to support such an assumption.
The facts are that certain shareholders with restricted shares elected not to have the restrictions lifted. That's all we know. Speculate all you want. The only thing of importance to me is that they made the decision. It says to me they have some faith in the company. If as Howard said, there are further restrictions due to being officers or affiliates, that does not dilute the fact that ultimately if they want to sell, that these restrictions must be lifted first. They opted to take a pass on that for now. I guess we're a little miffed that out theory of almost a billion shares hitting the market and driving the price down to say $.0005 isn't going to happen anytime soon.
Again, complete fabrication. There is nothing indicating that an SEC requirement says that the restrictions could not be lifted. Also, again, you have no proof that the shares being released will then be sold. Keep trying.
The 15c2-11 is an SEC required quarterly filing for pink sheet companies. The filing of the 15c2-11 with FINRA by a market maker has not yet been done, but is expected soon.
Thanks tb.
Tried that number and left voice mail messages. Haven't gotten any return calls. I was hoping someone might have a direct line.
Can anyone provide a good phone number to reach Howard? TIA
Another milestone met by the company, filing for uplisting.
It appears that this is the filing necessary for uplisting to the otcbb.
Haven't seen the Q yet. Anyone else?
Board members and officers do often act in the best interests of shareholders. I have seen it on numerous occasions with companies I have knowledge about. To suggest that such a suggestion is comical indicates that one believes the management of this company is less than honorable. While they may not have had success in the past and in fact made some mistakes, I have seen no indication of nefarious activity by this company and its current management. I would ask anyone that has proof otherwise to provide such information.
By the way ty, where was this from? It's great news.
Nice try dog. I have no answer to your questions. The positive info I offer is to refute the baseless claims you make. No one suggested that there was a humanitarian motive, but to say that insiders acting out of regard for shareholders is comical, is just your opinion and another baseless claim. I know many private companies (that have outside shareholders) that in fact do act in all shareholders' best interest. Is this so hard to believe? Your claims and insinuations of nefarious activity by this company is an issue and I will stick to it.
Dog, I have no problem with your questions or anyone else's questions for that matter. I just offered a very clear example of how your assumptions, supposedly based on facts had no merit.
You have provided no facts here dog, just questions and assumptions, which you are certainly entitled to make. You don't know if they are relevant or not since you have no answers. Follow your own words dog, "just the facts please". The "possible impact, if any, Granite might be having on ASFX trading activity" is pure speculation on your part. Did someone make you moderator and I missed it? I can make any suggestions I want, just as you continue to do so, without any basis in fact.
In answer to your questions, dog, there may be some who are unhappy with the extension. Nothing we can do about it and quite frankly, nothing extraordinary. I assume that all the necessary info was not completely reviewed and/or QC checklists completed by the accountants in time. I don't think we will see any earth shattering news in this Q. As far as all of your other questions, time will tell what the answers are and whether they are even relevant. I am willing to wait and my guess is so are many others. If it's too risky for you, I would suggest you move on.
It would seem to me that negative facilitators are trying to alter expectations of investors. True investors already know there is not much to expect from the second quarter. Not sure why there would be a lot of disappointed investors.
DR P,
Did you hear anything more on this?
TB,
He said he has a GTC order in for 500,000 at $.0005.
Not sure why that is relevant. Many companies that sell products do not necessarily identify the manufacturers. I see no mention of who produced the MVSS.
Not confusing at all. What Roth and Safeguard received for the patent is stock and a contingent note. Neither of these contributed to the deficit
That is your assumption dog. The s-1 lifts the restrictions allowing them to sell. You have no proof, as has been stated over and over, that they are planning to sell.
That is good dd dog. It shows that Pointe Resources is promoting the NDD. As far as the thermometer is concerned, I have not seen a picture of the clinical version, so I don't know if that is it, but let's assume that's not it. Pointe may have an existing contract that was signed before Massoglia joined ASFX in 2010. Or they may just be waiting for the clinical version to be ready for production before promoting it. Very good dog!
If the company fails, Roth will not end up with much at all.
Not sure what you mean by "Not this week was it"?
What does Marc Massoglia have to do with Pointe Resources?
No Roth did not give the NDD to ASFX for nothing. He received stock and a note (contingent). Neither of these contributed to the accumulated deficit. You need a basic accounting course.
ASR Family Marc Massoglia, senior vice president of sales for ASR, met with Xavier Billaut, product manager Betaferon for Bayer Schering Pharma, in Lille France this week to discuss expansion of the Disintegrator program for additional treatments in France and other Betaferon markets throughout the world. Mr. Billaut attributes ...much of the positive switch market share gain to the Disintegrator because it improves the lives of the patients. “I am sure that these patients come because of this [Disintegrator] device. I am very confident of that,” says Billaut discussing how Betaferon saw market share gains even in the face of a new lower cost competitor.
Jason Roth and Safeguard did not benefit via the accumulated deficit. They may ultimately benefit from the sale of the NDD patent to ASFX, however, this purchase by ASFX in no material way contributed to the deficit.